17,261 trials
Myotonic Dystrophy 1 · Excessive Daytime Sleepiness
Primary: Change in Excessive Daytime Sleepiness (EDS) Based on Change in Daytime Sleepiness Scale (DSS) Score — -3.8; -1.8; 0.0 score on a scale
Obesity, Morbid · Insulin Resistance
Primary: Change in Insulin Resistance Compared to Baseline — -0.25; 1.16; -0.04; 0.93 Index
Sarcoidosis
Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters
Dengue
Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days
Locally Advanced or Metastatic Urothelial Carcinoma
Primary: Overall Response Rate (ORR) — 48.5 Percentage of patients with response
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving a Successful Composite Clinical Response According to the Criteria for American College of Rheumatology 20% Response (ACR20) — 48.4…
Immunisation · Shigella Infection
Primary: The Proportion of Participants With Shigellosis Following Challenge With Shigella Sonnei 53G Through Day 63 in the Pooled Group of Participants Receiving Two Doses of…
Primary Biliary Cholangitis · Liver Stiffness
Primary: Change in ALP at Week 24 Compared to Baseline — 0.89; 0.84; 1.03 ratio — p=0.0206
Stroke · Depression
Primary: Change in Mean Score of Depression as Assessed by the Hamilton Rating Scale for Depression — 5.20; 2.17; 0.14 units on a scale
Colorectal Cancer · Colorectal Neoplasms · Colorectal Carcinoma
Primary: Percentage Change From Baseline in Tumour Size — 8.3; 2.9; 3.2; 2.3 Percent change
Anal High Grade Squamous Intraepithelial Lesion
Primary: Performance Characteristics: Sensitivity (SN), Specificity (SP), Positive Predictive Value (PPV) and Negative Predictive Values (NPV) — 90.0; 76.9; 100.0; 65.6…
Hearing Loss
Primary: Proportion of Participants With SENS-401 Detected in Perilymph — 15; 0 Participants
Autism Spectrum Disorder
Primary: Change From Baseline to Day 85 in the Autism Behavior Inventory (ABI) Core Domain Score (Social Communication and Restrictive Behaviour) — -0.20; -0.26 Score on a scale…
Alzheimer Disease
Primary: Change From Baseline in ADAS-Cog-11 — 11.05; 0.07; 14.26; 1.04 Change in scale units
Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Participants With a Response — 2; 2 Participants